Lipocalins in drug discovery: From natural ligand-binding proteins to 'anticalins'

Drug Discovery Today

Volumn 10, Issue 1, 2005, Pages 23-33

  Schlehuber, Steffen ^a   Skerra, Arne ^b  

^a Pieris Pharmaceuticals GmbH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bilin binding protein; Biochemistry; Calycin; Chemical Biology; Drug Discovery; Hapten; Pharmaceutical Science; Plasma protein; Protein engineering; Retinol binding protein

Indexed keywords

ANTICALIN; LIPOCALIN; PROTEIN; UNCLASSIFIED DRUG;

HUMAN; INSECT; LIGAND BINDING; MEMBRANE TRANSPORT; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; REVIEW; SOLUBILITY;

ANIMALS; ANTIDOTES; CARRIER PROTEINS; DRUG DESIGN; HUMANS; LIGANDS; PROTEIN BINDING; RETINOL-BINDING PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 12844276589     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03294-5     Document Type: Review

References (90)

1. Flower D.R. The lipocalin protein family: structure and function. Biochem. J. 318:1996;1-14
2. Skerra A. Lipocalins as a scaffold. Biochim. Biophys. Acta. 1482:2000;337-350
3. Flower D.R. Multiple molecular recognition properties of the lipocalin protein family. J. Mol. Recognit. 8:1995;185-195
4. Cowan S.W., et al. Crystallographic refinement of human serum retinol-binding protein at 2 Å resolution. Proteins. 8:1990;44-61
5. Newcomer M.E., et al. The three-dimensional structure of retinol-binding protein. EMBO J. 3:1984;1451-1454
6. Flower D.R. The lipocalin protein family: a role in cell regulation. FEBS Lett. 354:1994;7-11
7. 1-acid glycoprotein and serum retinol-binding protein and its relatives. FASEB J. 1:1987;209-214
8. Goetz D.H., et al. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell. 10:2002;1033-1043
9. Böcskei Z., et al. Pheromone binding to two rodent urinary proteins revealed by X-ray crystallography. Nature. 360:1992;186-188
10. Redl B. Human tear lipocalin. Biochim. Biophys. Acta. 1482:2000;241-248
11. Breustedt, D.A. et al. The 1.8 Å crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J. Biol. Chem (in press)
12. Schlehuber S., Skerra A. Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant - a so-called 'anticalin' - using a molecular random approach. Biophys. Chem. 96:2002;213-228
13. Müller H.N., Skerra A. Functional expression of the uncomplexed serum retinol-binding protein in Escherichia coli. Ligand binding and reversible unfolding characteristics. J. Mol. Biol. 230:1993;725-732
14. Campanacci V., et al. The crystal structure of the Escherichia coli lipocalin Blc suggests a possible role in phospholipid binding. FEBS Lett. 562:2004;183-188
15. Rassart E., et al. Apolipoprotein D. Biochim. Biophys. Acta. 1482:2000;185-198
16. Vogt M., Skerra A. Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H. J. Mol. Recognit. 14:2001;79-86
17. Fluckinger M., et al. Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob. Agents Chemother. 48:2004;3367-3372
18. Gasymov O.K., et al. Tear lipocalin: potential for selective delivery of rifampin. Biochim. Biophys. Acta. 1688:2004;102-111
19. Paesen G.C., et al. Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mol. Cell. 3:1999;661-671
20. Flower D.R. Beyond the superfamily: the lipocalin receptors. Biochim. Biophys. Acta. 1482:2000;327-336
21. Yang J., et al. An iron delivery pathway mediated by a lipocalin. Mol. Cell. 10:2002;1045-1056
22. Wojnar P., et al. Molecular cloning of a novel lipocalin-1 interacting human cell membrane receptor using phage display. J. Biol. Chem. 276:2001;20206-20212
23. Åkerström B., et al. Lipocalins: unity in diversity. Biochim. Biophys. Acta. 1482:2000;1-8
24. Flower D.R. Benzon symposium no. 50: the lipocalin protein superfamily. Targets. 2:2003;235-236
25. Zanotti G., Berni R. Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. Vitam. Horm. 69:2004;271-295
26. 1-Microglobulin: a yellow-brown lipocalin. Biochim. Biophys. Acta. 1482:2000;172-184
27. Ortlund E., et al. Crystal structure of human complement protein C8γ at 1.2 Å resolution reveals a lipocalin fold and a distinct ligand binding site. Biochemistry. 41:2002;7030-7037
28. Urade Y., Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim. Biophys. Acta. 1482:2000;259-271
29. Briand L., et al. Evidence of an odorant-binding protein in the human olfactory mucus: location, structural characterization, and odorant-binding properties. Biochemistry. 41:2002;7241-7252
30. Fournier T., et al. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta. 1482:2000;157-171
31. Dell A., et al. Structural analysis of the oligosaccharides derived from glycodelin, a human glycoprotein with potent immunosuppressive and contraceptive activities. J. Biol. Chem. 270:1995;24116-24126
32. Koistinen H., et al. Glycodelin and beta-lactoglobulin, lipocalins with a high structural similarity, differ in ligand binding properties. FEBS Lett. 450:1999;158-162
33. Biesalski H.K., et al. Biochemical but not clinical vitamin A deficiency results from mutations in the gene for retinol-binding protein. Am. J. Clin. Nutr. 69:1999;931-936
34. Routledge P.A. Clinical relevance of alpha-1-acid glycoprotein in health and disease. Prog. Clin. Biol. Res. 300:1989;185-198
35. Bruno R., et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin. Cancer Res. 9:2003;1077-1082
36. Muchitsch E.M., et al. Effects of alpha-1-acid glycoprotein in different rodent models of shock. Fundam. Clin. Pharmacol. 12:1998;173-181
37. Kuebler J.F., et al. Alpha-1-acid-glycoprotein protects against trauma-hemorrhagic shock. J. Surg. Res. 119:2004;21-28
38. Halttunen M., et al. Glycodelin: a reproduction-related lipocalin. Biochim. Biophys. Acta. 1482:2000;149-156
39. Oehninger S., et al. Factors affecting fertilization: endometrial placental protein 14 reduces the capacity of human spermatozoa to bind to the human zona pellucida. Fertil. Steril. 63:1995;377-383
40. Chiu P.C., et al. Zona-binding inhibitory factor-1 from human follicular fluid is an isoform of glycodelin. Biol. Reprod. 69:2003;365-372
41. Seppala M. Advances in uterine protein research: reproduction and cancer. Int. J. Gynaecol. Obstet. 85:2004;105-118
42. Rachmilewitz J., et al. Focal localization of placental protein 14 toward sites of TCR engagement. J. Immunol. 168:2002;2745-2750
43. Yaniv E., et al. Placental protein 14 regulates selective B cell responses. Cell. Immunol. 222:2003;156-163
44. Mukhopadhyay D., et al. Glycodelin A, not glycodelin S, is apoptotically active. Relevance of sialic acid modification. J. Biol. Chem. 279:2004;8577-8584
45. Clark G.F., et al. A role for glycoconjugates in human development: the human feto-embryonic defence system hypothesis. Hum. Reprod. 11:1996;467-473
46. Seppala M., et al. Glycodelins GdA and GdS modified by 3-hydroxyphthalic anhydride inhibit gp120-CD4 binding and HIV-1 infection. in vitro. Lab. Invest. 77:1997;127-130
47. Van den Nieuwenhof I.M., et al. Recombinant glycodelin carrying the same type of glycan structures as contraceptive glycodelin-A can be produced in human kidney 293 cells but not in Chinese hamster ovary cells. Eur. J. Biochem. 267:2000;4753-4762
48. Ribeiro J.M., et al. Exploring the sialome of the blood-sucking bug Rhodnius prolixus. Insect Biochem. Mol. Biol. 34:2004;61-79
49. Mans B.J., Neitz A.W. Adaptation of ticks to a blood-feeding environment: evolution from a functional perspective. Insect Biochem. Mol. Biol. 34:2004;1-17
50. Noeske-Jungblut C., et al. Triabin, a highly potent exosite inhibitor of thrombin. J. Biol. Chem. 270:1995;28629-28634
51. Fuentes-Prior P., et al. Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibitor derived from a triatomine bug. Proc. Natl. Acad. Sci. U. S. A. 94:1997;11845-11850
52. Glusa E., et al. Inhibition of thrombin-mediated cellular effects by triabin, a highly potent anion-binding exosite thrombin inhibitor. Thromb. Haemost. 77:1997;1196-1200
53. Kemp D.H., Bourne A. Boophilus microplus: the effect of histamine on the attachment of cattle-tick larvae - studies in vivo and in vitro. Parasitology. 80:1980;487-496
54. Couillin I., et al. Arthropod-derived histamine-binding protein prevents murine allergic asthma. J. Immunol. 173:2004;3281-3286
55. Montfort W.R., et al. Nitrophorins and related antihemostatic lipocalins from Rhodnius prolixus and other blood-sucking arthropods. Biochim. Biophys. Acta. 1482:2000;110-118
56. Bredt D.S., Snyder S.H. Nitric oxide: a physiologic messenger molecule. Annu. Rev. Biochem. 63:1994;175-195
57. Weichsel A., et al. Crystal structures of a nitric oxide transport protein from a blood-sucking insect. Nat. Struct. Biol. 5:1998;304-309
58. Francischetti I.M., et al. Purification, cloning, expression, and mechanism of action of a novel platelet aggregation inhibitor from the salivary gland of the blood-sucking bug, Rhodnius prolixus. J. Biol. Chem. 275:2000;12639-12650
59. Sarkis J.J., et al. Salivary apyrase of Rhodnius prolixus. Kinetics and purification. Biochem. J. 233:1986;885-891
60. Francischetti I.M., et al. Biochemical and functional characterization of recombinant Rhodnius prolixus platelet aggregation inhibitor 1 as a novel lipocalin with high affinity for adenosine diphosphate and other adenine nucleotides. Biochemistry. 41:2002;3810-3818
61. Skerra A. Imitating the humoral immune response. Curr. Opin. Chem. Biol. 7:2003;683-693
62. Schmidt F.S., Skerra A. The bilin-binding protein of Pieris brassicae. cDNA sequence and regulation of expression reveal distinct features of this insect pigment protein. Eur. J. Biochem. 219:1994;855-863
63. Huber R., et al. Molecular structure of the bilin binding protein (BBP) from Pieris brassicae after refinement at 2.0 Å resolution. J. Mol. Biol. 198:1987;499-513
64. Beste G., et al. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc. Natl. Acad. Sci. U. S. A. 96:1999;1898-1903
65. Skerra A. 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties. J. Biotechnol. 74:2001;257-275
66. Schlehuber S., et al. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J. Mol. Biol. 297:2000;1105-1120
67. Mercader J.V., Skerra A. Generation of anticalins with specificity for a nonsymmetric phthalic acid ester. Anal. Biochem. 308:2002;269-277
68. Korndörfer I.P., et al. Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. J. Mol. Biol. 330:2003;385-396
69. Korndörfer I.P., et al. Crystallographic analysis of an 'anticalin' with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region. Proteins. 53:2003;121-129
70. Vogt M., Skerra A. Construction of an artificial receptor protein ('anticalin') based on the human apolipoprotein D. Chembiochem. 5:2004;191-199
71. Hauptman P.J., Kelly R.A. Digitalis. Circulation. 99:1999;1265-1270
72. Ward S.B., et al. Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind. Ther. Drug Monit. 22:2000;599-607
73. Lechat P., et al. Reversal of lethal digoxin toxicity in guinea pigs using monoclonal antibodies and Fab fragments. J. Pharmacol. Exp. Ther. 229:1984;210-213
74. Kelly R., et al. Reversal of digoxin cardiac toxicity by an anticalin (Digical II) in the anaesthetized guinea pig. Abstracts of The Physiological Society Meeting. 1-3 September, 2004;30P-31P University College Cork, Ireland
75. Leach D.R., et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1996;1734-1736
76. Davis S.J., et al. The nature of molecular recognition by T cells. Nat. Immunol. 4:2003;217-224
77. Madrenas J., et al. Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand. J. Immunol. 172:2004;5948-5956
78. Keler T., et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. 171:2003;6251-6259
79. Phan G.Q., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 100:2003;8372-8377
80. Camacho L.H., et al. Phase I clinical trial of anti-CTLA-4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. J Clin. Oncol. (Meeting Abstracts). 22:(Suppl. 14):2004;2505
81. Skerra, A. and Schlehuber, S. (2003) PIERIS Proteolab AG. Muteins of human neutrophil gelatinase-associated lipocalin and related proteins, WO 03/029463 A2
82. Lane P. Regulation of T and B Cell responses by modulating interactions between CD28/CTLA-4 and their ligands, CD80 and CD86. Ann. N. Y. Acad. Sci. 815:1997;392-400
83. Samama M.M., Gerotziafas G.T. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb. Res. 109:2003;1-11
84. Constantinides P.P., et al. Tocol emulsions for drug solubilization and parenteral delivery. Adv. Drug Deliv. Rev. 56:2004;1243-1255
85. Perez E.A. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest. 19:2001;155-164
86. Schlehuber S., Skerra A. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol. Chem. 382:2001;1335-1342
87. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer. 1:2001;118-129
88. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2:2003;214-221
89. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24:2002;1720-1740
90. Virtanen T., et al. Allergy to lipocalins: a consequence of misguided T-cell recognition of self and nonself? Immunol. Today. 20:1999;398-400